trending Market Intelligence /marketintelligence/en/news-insights/trending/j9ohvnocwlj1ppt1eadgpg2 content esgSubNav
In This List

US FDA panel recommends against approving INSYS painkiller spray

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


US FDA panel recommends against approving INSYS painkiller spray

An expert panel convened by the U.S. Food and Drug Administration voted not to recommend the approval of INSYS Therapeutics Inc.'s buprenorphine spray to treat moderate to severe acute pain.

The FDA is not required to act on the advice of its advisory panels but generally does so.

INSYS said it will continue to work with the U.S. regulator for its buprenorphine product candidate and to "build on the current body of evidence for its efficacy and safety."